← Back to Search

Monoclonal Antibodies

Imsidolimab low dose for Pustular Psoriasis (GEMINI1 Trial)

Phase 3
Waitlist Available
Research Sponsored by AnaptysBio, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 4
Awards & highlights

GEMINI1 Trial Summary

This trial is testing a new drug for people with psoriasis to see if it is better than the current standard of care.

Eligible Conditions
  • Generalized Pustular Psoriasis

GEMINI1 Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 4
This trial's timeline: 3 weeks for screening, Varies for treatment, and week 4 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Proportion of subjects achieving Generalized Pustular Psoriasis Physician's Global Assessment (GPPPGA) score of 0 (clear) or 1 (almost clear)

GEMINI1 Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: IV low dose Imsidolimab, other name ANB019Experimental Treatment1 Intervention
ANB019 Biological Humanized Monoclonal Antibody Low Dose
Group II: IV high dose Imsidolimab, other name ANB019Experimental Treatment1 Intervention
ANB019 Biological Humanized Monoclonal Antibody High Dose
Group III: IV PlaceboPlacebo Group1 Intervention
Placebo Solution
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Imsidolimab
Not yet FDA approved
Imsidolimab
Not yet FDA approved

Find a Location

Who is running the clinical trial?

AnaptysBio, Inc.Lead Sponsor
16 Previous Clinical Trials
1,603 Total Patients Enrolled
Bruce Randazzo, MDStudy DirectorAnaptysBio, Inc.
10 Previous Clinical Trials
774 Total Patients Enrolled

Media Library

Imsidolimab (Monoclonal Antibodies) Clinical Trial Eligibility Overview. Trial Name: NCT05352893 — Phase 3
Pustular Psoriasis Research Study Groups: IV Placebo, IV high dose Imsidolimab, other name ANB019, IV low dose Imsidolimab, other name ANB019
Pustular Psoriasis Clinical Trial 2023: Imsidolimab Highlights & Side Effects. Trial Name: NCT05352893 — Phase 3
Imsidolimab (Monoclonal Antibodies) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05352893 — Phase 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are elderly people welcome in this trial?

"The age range for eligible participants in this research study is between 18 and 80 years old."

Answered by AI

Are there many places in the city where this research is taking place?

"5 sites are recruiting patients for this study, for example Site 102 in Springville, Site 109 in Largo, and Site 101 in Ann Arbor. Other locations include 5 other sites."

Answered by AI

Are there any patients currently still being recruited for this trial?

"Currently, this clinical trial is recruiting patients. The first posting for this trial was on April 14th, 2022 and the most recent update was on May 2nd, 2022."

Answered by AI

Do I fit the bill to participate in this research?

"For this particular trial, dermatologists are looking for 45 patients that have psoriasis, are between 18-80 years old, and also meet the following conditions: a BSA of ≥5% that is covered in pustules (not including palms or soles), a GPPPGA score of ≥3, and a PRS score of ≥3."

Answered by AI

What is the Imsidolimab dosage that the FDA has deemed safe?

"Imsidolimab low dose safety is rated highly by our team at Power. It is a Phase 3 trial, so there is some evidence of efficacy and multiple rounds of data that support its safety."

Answered by AI

Who else is applying?

What state do they live in?
Kentucky
How old are they?
18 - 65
What site did they apply to?
Site 105
What portion of applicants met pre-screening criteria?
Met criteria

How responsive is this trial?

Most responsive sites:
  1. Site 105: < 48 hours
Typically responds via
Phone Call
Email
Average response time
  • < 2 Days
Recent research and studies
clinicaltrials.govStudy
Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With GPP
2022. "Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With GPP". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05352893.
~15 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top